Dive into the archives.
- Dirucotide Does Not Meet Primary Endpoint in Phase III Trial In Secondary Progressive MS
July 27, 2009 – Eli Lilly and Company and BioMS Medical Corp. today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no [...]
- Product Overview – DIRUCOTIDE
Product Overview – DIRUCOTIDE Dirucotide (formally named MBP8298) is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (MBP). Dirucotide has been developed for the treatment of multiple sclerosis (specifically secondary progressive MS) and is based on over 26 years [...]
- Dirucotide (BioMS) Phase III U.S. Trial Gets Positive Safety Review From Data Safety Monitoring Board
Edmonton, Alberta, April 14, 2009 – BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company’s U.S. pivotal phase III MAESTRO-03 trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended [...]
- SPMS Treatment Update: Spotlight on dirucotide (BioMS Medical Corp.)
BioMS Medical Announces 2008 Year End Results Edmonton, Alberta, March 17, 2009 – BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008. “Dirucotide has demonstrated the ability to safely affect MS progression in previous studies and [...]
